A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer

Trial Profile

A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Paclitaxel trevatide (Primary) ; Trastuzumab
  • Indications Brain metastases; Breast cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Apr 2013 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
    • 01 Dec 2012 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top